On September 24, 2025, Harrow, Inc. entered into a merger agreement to acquire the remaining equity in Melt Pharmaceuticals, following a previous interest reported on September 8, 2025; the deal involves an initial payment of $4.3 million, with potential future payments totaling up to approximately $348.2 million based on certain milestones.